Floatz logo

Copper Cu 64 Anti-Cea Monoclonal Antibody M5A

Liver and Intrahepatic Biliary Tract Cancer

City of Hope Medical Centermonoclonal_antibodyN/AActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Liver and Intrahepatic Biliary Tract Cancer cohort.

Asset / SponsorPhaseRating
IMMUNOGLOBULIN G1, ANTI-(HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR TYPE VEGFR-2 EXTRACELLULAR DOMAIN) (HUMAN MONOCLONAL IMC-1121B .GAMMA.-CHAIN), DISULPHIDE WITH HUMAN MONOCLONAL IMC-1121B .KAPPA.-CHAIN, DIMER
M.D. Anderson Cancer Center
Phase 2B
azd6244
National Cancer Institute (NCI)
Phase 2B
Floxuridine
OHSU Knight Cancer Institute
Phase 2CCC
DEXAMETHASONE
OHSU Knight Cancer Institute
Phase 2CCC
Eloxatin
OHSU Knight Cancer Institute
Phase 2CCC

View all 9 →

Same molecule, other indications

Copper Cu 64 Anti-Cea Monoclonal Antibody M5A is also rated in:

rectal cancerDormant
C
Indicative ·
39 / 100
View asset →
rectal carcinomaDormant
C
Indicative ·
39 / 100
View asset →
extrahepatic bile duct carcinomaDormant
D
Indicative ·
30 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →